摘要
The COVID-19 pandemic has caused severe health problems worldwide and unprecedented decimation of the global economy.Moreover,after more than 2 years,many populations are still under pressure of infection.Thus,a broader perspective in developing antiviral strategies is still of great importance.Inspired by the observed multiple benefits of heparin in the treatment of thrombosis,the potential of low molecular weight heparin(LMWH)for the treatment of COVID-19 have been explored.Clinical applications found that LMWH decreased the level of inflammatory cytokines in COVID-19 patients,accordingly reducing lethality.Furthermore,several in vitro studies have demonstrated the important roles of heparan sulfate in SARS-CoV-2 infection and the inhibitory effects of heparin and heparin mimetics in viral infection.These clinical observations and designed studies argue for the potential to develop heparin mimetics as anti-SARS-CoV-2 drug candidates.In this review,we summarize the properties of heparin as an anticoagulant and the pharmaceutical possibilities for the treatment of virus infection,focusing on the perspectives of developing heparin mimetics via chemical synthesis,chemoenzymatic synthesis,and bioengineered production by microbial cell factories.The ultimate goal is to pave the eminent need for exploring novel compounds to treat coronavirus infection-caused diseases.
基金
support from the National Key Research and Development Program of China (2021YFF0600700,2020YFA090032 and 2019YFA0906201)
the Swedish research council (2020-05759)
the National Natural Science Foundation of China (31720103901,31961133004,21907031,21977029,22108266).
